Corticosteroids in Ocular Tuberculosis
Yes, corticosteroids are indicated in ocular tuberculosis, but they must always be given concurrently with appropriate antitubercular therapy (ATT) to prevent disease progression while controlling the inflammatory response.
Evidence-Based Rationale
The use of corticosteroids in ocular TB is supported by extrapolation from other forms of extrapulmonary tuberculosis where inflammation causes significant tissue damage. While major TB guidelines do not specifically address ocular TB, they establish clear precedent for adjunctive steroid use in tuberculous meningitis and pericarditis—conditions where host inflammatory response drives morbidity 1.
Key Principles from Guidelines
Corticosteroids are beneficial when inflammation threatens tissue function:
- The European Respiratory Society states that corticosteroid use is justified by their anti-inflammatory activity in a disease where host response plays a major role 1
- Long-term benefits include reduced mortality in pericarditis and decreased neurological sequelae in meningitis 1
- Short-term benefits include faster clinical improvement in tuberculous meningitis, pericarditis, and pleuritis 1
The eye parallels the central nervous system in vulnerability to inflammatory damage:
- Like tuberculous meningitis, ocular TB involves a confined anatomical space where inflammation can cause irreversible damage 2
- The inflammatory component results from type IV hypersensitivity reaction, similar to meningeal and pericardial involvement 2
Clinical Application to Ocular TB
When to Use Steroids
Initiate corticosteroids in ocular TB when:
- Active intraocular inflammation is present (uveitis, chorioretinitis, papilledema) 2, 3
- Vision-threatening inflammation exists 2
- Bilateral involvement suggests severe inflammatory response 2
Critical Safety Requirements
Never use steroids without concurrent ATT:
- A case report demonstrates the danger: a patient developed worsening bilateral tuberculous chorioretinopathy with numerous white patches after corticosteroid monotherapy was initiated for presumed non-infectious papilledema 2
- This represents the "double-edged sword" of steroid treatment—it can worsen infection if ATT is not given simultaneously 2
Practical Treatment Protocol
Standard approach based on UK surveillance data:
- 60% of ocular TB patients in the UK were commenced on a reducing course of oral steroids alongside ATT 3
- First-line ATT consists of isoniazid, rifampicin, ethambutol, and pyrazinamide for at least 6 months 3
- Typical steroid dosing: prednisone 20-60 mg/day with gradual taper 1
Expected outcomes with combined therapy:
- 83% of patients achieved complete resolution of active clinical signs at 1-year follow-up 3
- Mean visual acuity improved from +0.41 LogMAR at presentation to +0.31 LogMAR at 12 months 3
Important Caveats
Diagnostic Uncertainty
Ocular TB remains largely a presumptive diagnosis:
- The clinical spectrum is wide and should be considered in any chronic or acute recurrent intraocular inflammation 2, 4
- Vitreous samples are often negative on direct examination, culture, and PCR 2
- There is currently no consensus on diagnostic criteria or standardized terminology 4
Special Populations
Use caution in HIV-infected patients:
- The European Respiratory Society warns that corticosteroids should be used with caution in HIV-infected patients 1, 5
- One study showed increased risk for Kaposi sarcoma with prednisolone in HIV-associated tuberculous pleurisy 1
Drug Interactions
Consider rifampin interactions:
- Rifampin induces hepatic enzymes and may reduce corticosteroid effectiveness 1
- Higher steroid doses or more frequent monitoring may be needed 1
Common Pitfalls to Avoid
Starting steroids before ATT: This can lead to disease progression and worsening outcomes 2
Assuming steroid responsiveness excludes TB: Ocular TB can be responsive or non-responsive to steroids, so response does not rule out the diagnosis 2
Premature steroid discontinuation: Use a gradual taper over weeks, similar to the 6-8 week protocols used in tuberculous meningitis 5, 6
Inadequate ATT duration: Treat for at least 6 months, with some experts recommending 9-12 months for severe cases 1, 3